Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. - Wikidata - awgldk - TriplyDB

Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml.

Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml.

http://www.wikidata.org/entity/Q36837061

about

Overdiagnosis and overtreatment of prostate cancer Management of low (favourable)-risk prostate cancer Single high intensity focused ultrasound session as a whole gland primary treatment for clinically localized prostate cancer: 10-year outcomes Prostate-specific antigen testing across the spectrum of prostate cancer.Novel therapies for metastatic castrate-resistant prostate cancer.Prostate cancer detection: a view of the future.Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.Predictors of repeated PSA testing among black and white men from the Maryland Cancer Survey, 2006 Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.Active surveillance for prostate cancer: an underutilized opportunity for reducing harm.An economic analysis of conservative management versus active treatment for men with localized prostate cancer Improving the communication of benefits and harms of treatment strategies: decision AIDS for localized prostate cancer treatment decisions The impact of PSA testing frequency on prostate cancer incidence and treatment in older men.Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.Does true Gleason pattern 3 merit its cancer descriptor?Prostate Cancer Care Before and After Medicare Eligibility.Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less.Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer.Prostate-specific antigen screening for prostate cancer in older men in the United States of America.Decision-making processes among men with low-risk prostate cancer: A survey study.Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes.SHISA2 enhances the aggressive phenotype in prostate cancer through the regulation of WNT5A expression.Individualizing PSA Monitoring Among Older Prostate Cancer Survivors.Treatment patterns for older veterans with localized prostate cancer.

P2860

Q26859596-4AAF6AE7-83D3-407E-B412-796A185FC1E1 Q26996501-55BA2728-F328-4CFB-929A-461C3FBE8E78 Q33873770-B7047C10-6455-41B5-BF66-5DCF10AB60A1 Q34210163-A0626474-2CDD-49FC-82CF-F05B1B6D348F Q34249263-FD5FE646-C449-4854-962B-A29F28E265EB Q34699342-E17E8A32-35C2-4973-92CE-2DABB6F4704C Q35089983-8DFAAAD2-5D64-4AC9-B7B0-F50E4BB320D9 Q35235153-E9C3FC35-6602-46CE-838F-42133C5557AD Q35752688-8CAC198C-DD80-42AE-9679-2A05C85092CF Q36520443-21DAE7C3-8BB7-4204-BC38-16FDDB95D638 Q36520468-97E44346-1B69-4E82-912E-E64C38BC6964 Q36520523-28DB0186-B3FD-46F3-B356-90D46957AD8A Q36831317-C739608C-9BF7-433A-BA6E-50A7B14E8A7C Q37302853-3129D225-1705-4D7A-9B33-A209B7B9C889 Q38928930-CC5BC861-501B-4778-88B2-E90E337A19D2 Q39776492-54BB4242-86E4-42DB-85BA-C5A1D6F5B1B6 Q41810505-569E77F4-8AB0-47E8-A4A6-40C4004218F0 Q42265374-DF8C692B-B01A-4F2B-A5F4-CEE5297BC3FB Q45168057-F0167FA8-3B12-4B6A-BE36-B0B4197F06F5 Q46259067-985C07CA-6302-4BAD-A384-F347E3163444 Q47212709-4C9CB78D-8BBF-4486-AC15-AF5A034BB51E Q49170846-AA9AD728-1A57-4236-ACED-21091A0A4BE2 Q50125689-3E8DE2DA-DBE1-49C5-A080-4A57DF7973C9 Q53400113-D56EEF8E-B535-457C-B710-D7C72BC2F8D0

P2860

Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml.

http://www.wikidata.org/entity/Q36837061

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Risk profiles and treatment pa ...... antigen level below 4.0 ng/ml.

@en

type

label

Risk profiles and treatment pa ...... antigen level below 4.0 ng/ml.

@en

prefLabel

Risk profiles and treatment pa ...... antigen level below 4.0 ng/ml.

@en

P1433

Q36837061-17AE8D4C-28BA-4D34-911F-D40516D2AEA9

P1476

Q36837061-74DF333B-841E-467B-A5C6-A9A038DD192B

P2093

Q36837061-0726510E-55D7-4D26-B3FE-6BC9D8C38495

Q36837061-1041419E-95A5-405A-B09A-575812B437D8

Q36837061-12EF0AC4-A6A4-4B03-8267-0B14A7DFE95E

Q36837061-46D8084A-5C0E-4147-AFC2-E6A7C96CE48E

Q36837061-5AB7CFDE-BA86-41AB-9AF6-9E2CB7EFEC55

Q36837061-6E85D307-768E-4709-9D0D-7D97F1E711E9

Q36837061-97637980-1F67-4E81-AEB8-AC8B1BDB36BA

Q36837061-B8FE7EBB-911A-437A-8EC9-BD29B22EAF93

P2860

Q36837061-0E787E79-FAA4-453F-AE20-10C517C1335B

Q36837061-235EEB49-2F2D-4EB3-9ACA-D152D545021D

Q36837061-2FDDF517-8D19-47E6-8CDB-110EA7CCEE1D

Q36837061-3FDA69DE-5701-4653-B7C6-A035D8392ACD

Q36837061-5D49BA8D-B485-4CAC-904A-971AFCEF515F

Q36837061-75199E85-665C-43A0-A509-172CD48C8DD9

Q36837061-76FEE297-9F87-4E72-8328-418C67F3FF76

Q36837061-85EA88EA-EE8C-4B07-80B1-1DF352E19859

Q36837061-8989F1F2-4C1E-4AC7-835E-954D2409CF74

Q36837061-8AA33E1A-B824-46FF-96F5-92282C1D95D3

P304

Q36837061-798FE5F2-3D2C-45D9-AF4A-2A681085325E

P31

Q36837061-1DF411BE-8E0B-414C-BF7D-D3FD9765264E

P356

Q36837061-A5A32FEF-549C-409F-8050-385562DBE91E

P407

Q36837061-2477DD2C-2886-4DD8-8FC9-BA4B432AAB5C

P433

Q36837061-AA3DBC19-B8C9-4DF3-ACC5-A1F3C840A3C3

P478

Q36837061-C45F3BC9-204E-45F0-B4D0-950DCB3F7B20

P577

Q36837061-87A13A50-FF6F-41E2-935A-7F4EC10B4BA4

P5875

Q36837061-39B96617-649E-43A9-B366-07486CE3DC82

P698

Q36837061-6073E252-8525-4FE3-9CF0-1C60FB81C6EA

P932

Q36837061-9D314E1F-8C72-4EBD-8B68-B3AE0BF44147

P356

ARCHINTERNMED.2010.221

P1433

JAMA Internal Medicine

P1476

Risk profiles and treatment pa ...... antigen level below 4.0 ng/ml.

@en

P2093

Amit R Mehta

http://www.w3.org/2001/XMLSchema#string

Calpurnyia B Roberts

http://www.w3.org/2001/XMLSchema#string

Grace L Lu-Yao

http://www.w3.org/2001/XMLSchema#string

Mark N Stein

http://www.w3.org/2001/XMLSchema#string

Peter C Albertsen

http://www.w3.org/2001/XMLSchema#string

Robert S DiPaola

http://www.w3.org/2001/XMLSchema#string

Yong Lin

http://www.w3.org/2001/XMLSchema#string

Yu-Hsuan Shao

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2008

Screening and prostate-cancer mortality in a randomized European study

Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Survival following primary androgen deprivation therapy among men with localized prostate cancer

Health-related quality of life in treatment for prostate cancer: looking beyond survival.

P304

1256-1261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHINTERNMED.2010.221

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

170

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45366451

http://www.w3.org/2001/XMLSchema#string

P698

20660846

http://www.w3.org/2001/XMLSchema#string

P932

3651841

http://www.w3.org/2001/XMLSchema#string